Quintiles Launches Innovative Center of Excellence in Dalian, China

Quintiles Launches Innovative Center of Excellence in Dalian, China
Language, cultural knowledge and location ideal for Japan, China and Korean markets

BEIJING & SINGAPORE -- Quintiles today announced the opening of a business process outsourcing (BPO) and project management center of excellence in Dalian, a major city in northeast China with a multilingual workforce and location ideally suited to serve the Japanese, Chinese and South Korean biopharmaceutical markets.

The Dalian office will provide data management, biostatistics, medical writing, pharmacovigilance, post-marketing safety surveillance and back-office support for administrative functions for global and local biopharma companies. The office also will support clinical operations for study sites in northeast China.

Dalian's strategic location and talent pool will allow Quintiles to provide clinical services in English, Japanese, Korean and Mandarin (Dalian's local workforce is not only multilingual but also has a cultural understanding of its neighboring countries), a valuable offering for both North Asian and global customers seeking to expand in the region or who want to ensure business continuity through resource diversification.

"Following the success of Quintiles' Bangalore BPO center, which has over 1,000 people supporting global studies, the Dalian Center of Excellence will provide a North Asia support structure for our growing business in Japan, Korea and China," said Anand Tharmaratnam, Senior Vice President and Head of Asia Markets, Quintiles. "Furthermore, the Dalian team will be well-suited for clients seeking to diversify their outsourcing locations for business continuity assurance."

Quintiles anticipates growing the center to 500 staff in the next several years once all services are fully established. It will be the company's fourth hub office in Greater China (in addition to Beijing, Shanghai and Hong Kong).

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com .

SOURCE: Quintiles

        Stacey Hara, Media Relations Asia Pacific, +65 6602 1583
        [email protected]
        Jay Johnson, Media Relations U.S., +1 919 998 2066
        [email protected]
        Greg Connors, Investor Relations, +1 919 998 2000
        [email protected]

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.